글로벌 알파1-안티트립신 결핍 치료 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 통찰력

어떤 종류의 심혈관 질환이나 장애를 앓고 있는 사람은 간과 폐에 심각한 손상을 주는 요인을 초래할 수 있습니다. 알파1-안티트립신은 그러한 생명을 위협하는 질병 중 하나입니다. 이것은 완전히 치료할 수 없는 유전적 질환이지만 어느 정도 관리할 수 있습니다. 알파1-안티트립신 결핍을 앓고 있는 사람의 신체는 충분한 알파1-안티트립신 단백질을 생산할 수 없게 됩니다. 이것은 특정 개인의 신체에 부정적인 영향을 미칩니다.    

• 알파1-안티트립신 결핍증 치료는 지지적이며 증상의 심각성을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 알파1-안티트립신 결핍증 치료 시장이 2022년에서 2029년까지의 예측 기간 동안 10.07%의 CAGR로 성장할 것이라고 분석합니다.

알파1-안티트립신 결핍증 치료 시장 동향

운전자

• 노령인구 기반

노령 인구는 호흡기 및 심혈관 질환을 앓을 가능성이 더 높습니다. 폐기종 질환, 간경변, 만성 폐쇄성 폐질환(COPD) 및 기타 만성 질환은 충분한 알파1-안티트립신 단백질을 배양하는 데 책임이 있는 신체의 세포를 손상시키는 원인이 됩니다. 따라서 이 요인은 알파1-안티트립신 결핍 치료 시장의 성장 범위를 확대할 것입니다.     

• 의료 인프라에 대한 투자 증가

알파1-안티트립신 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라 개선에 도움이 되는 의료비 지출 증가입니다. 특히 개발도상국에서 의료 산업의 성장과 확장은 신기술과 첨단 의료 기술, 장비 및 약물의 사용과 적용을 초대할 것입니다. 이는 알파1-안티트립신 결핍 치료에 대한 수요를 직접적으로 증가시킬 것입니다.

• 연구개발 활동

공공 및 민간 시장 참여자 간의 전략적 협력이 증가함에 따라 매일 연구 개발 활동의 수가 증가하고 있습니다. 이러한 연구 개발 능력은 알파1-안티트립신 결핍 치료에 대한 수요를 촉진할 신약 및 의료 기술 분야에서 수행되고 있습니다.

Furthermore, rising number of genetic tests, blood tests, and biopsy tests, rising initiatives by public and private organizations to spread awareness and well-organized distribution network of leading manufacturers are the factors that will expand the market growth rate. Other factors such as increase in the demand for effective therapies and rising adoption rate for early diagnostic procedures will positively impact the market's growth rate.

Opportunities

Rise in the level of personal disposable income and growing awareness in the developing economies pertaining to the availability of treatment options will further create lucrative market growth opportunities. Rising medical tourism globally, increase in the prescription for combination therapies and high potential of growth in the untapped market will create enough market growth opportunities.  

Restraints/Challenges

However, high costs associated with research and development proficiencies will emerge as one of the biggest restraints for the market. Dearth of awareness and required infrastructural facilities in the underdeveloped and backward economies and slow diagnosis rates of alpha1-antitrypsin deficiency will further derail the market growth rate. Slow rate of approval for drugs and inhibitors, very less availability of plasma fractionation capacity and increasing cases of patent expiry will also challenge the market growth rate. 

This alpha1-antitrypsin deficiency treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on alpha1-antitrypsin deficiency treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to Kamada Ltd, in United States, there are at the moment 100,000 individuals suffering from alpha1-antitrypsin deficiency. 

The alpha1-antitrypsin deficiency treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Alpha1-Antitrypsin Deficiency Treatment Market

COVID-19 has led to denting the alpha1-antitrypsin deficiency treatment market growth rate. The consumer demand has subsequently reduced owing to the increased focus towards reducing non-essential expenses. Further, supply chain disruptions owing to restrictions and lockdown have hampered to effectivity of online and offline distribution channels. However, it must be noted that the post pandemic phase will generate lucrative growth opportunities for the alpha1-antitrypsin deficiency treatment market.

Recent Development

• Green signal by the regulatory authorities in Europe is anticipated to propel growth in the demand for Respreeza/Zemaira  by the end of 2028.
• In September 2019, Kamada Ltd., extended their strategic supply to Takeda Pharmaceutical Company Limited produce Alpha 1 Proteinase Inhibitor for humans called ‘Glassia’ through 2021.

Global Alpha1-Antitrypsin Deficiency Treatment Market Scope

The alpha1-antitrypsin deficiency treatment market is segmented on the basis of treatment type, route of administration and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Augmentation Therapy
• Bronchodilators
• Corticosteroids
• Oxygen Therapy
• Others

Based on treatment type, the alpha1-antitrypsin deficiency treatment market is segmented into augmentation therapy, bronchodilators, corticosteroids and oxygen therapy. Augmentation therapy has been further segmented into aralast, prolastin, zemaira/respreeza and glassia.

Route of Administration

• Parenteral
• Inhalation
• Oral

Based on route of administration, the alpha1-antitrypsin deficiency treatment market is segmented into parenteral, inhalation and oral.

End User

• Hospitals
• Specialty Clinics
• Pharmacies

Alpha1-antitrypsin deficiency treatment market is also segmented on the basis of end user is segmented into hospitals, specialty clinics and pharmacies.

Pipeline Analysis

In april 2019, Zemaira, an alpha 1 proteinase inhibitor for humans was approved by the United States Food and Drug Association, thereby allowing CSL Behring to offer these inhibitors in 4 as well as 5 gram vials. Takeda Pharmaceutical Company Limited, Kamada Pharmaceuticals, AstraZeneca, Pfizer, Inc., LFB Biomedicaments S. A., GlaxoSmithKline PLC, Boehringer Ingelheim GmbH and others are the involved in the development of potential drugs for the improvement of treatmentof alpha1-antitrypsin deficiency.

Alpha1-Antitrypsin Deficiency Treatment Market Regional Analysis/Insights

The alpha1-antitrypsin deficiency treatment market is analysed and market size insights and trends are provided by country, treatment type, route of administration and end user as referenced above.

The countries covered in the alpha1-antitrypsin deficiency treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the alpha1-antitrypsin deficiency treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players, well-developed healthcare infrastructure in this region and rising cases of respiratory disorders. Europe on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increasing patient pool and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Alpha1-Antitrypsin Deficiency Treatment Market Share Analysis

The alpha1-antitrypsin deficiency treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to alpha1-antitrypsin deficiency treatment market.

알파1-안티트립신 결핍 치료 시장에서 활동하는 주요 기업으로는 Grifols, SA, Kamada Pharmaceuticals., CSL, Arrowhead Pharmaceuticals, Inc., CHIESI Farmaceutici SpA, AstraZeneca, Henry Schein, Inc., Healthy Life Pharma Private Limited., Hovione, Switzer Life science Pvt. Ltd., Cyndea Pharma, Anuh Pharma Ltd., Cipla Inc., Pfizer Inc., Anantco Enterprises Pvt. Ltd., Novo Nordisk A/S, Otsuka America Pharmaceutical, Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, WOCKHARDT 등이 있습니다.

SKU-52167